Results 41 to 50 of about 310,229 (264)

Sustainable bioplastics manufacturing from renewable sources

FEBS Open Bio, EarlyView.
Bioplastics are manufactured by using polymers from different bio‐based sources. These novel materials not only offer biodegradability but also possess various functional properties that make them suitable for diverse applications. Recent developments in the preparation of bioplastics are reported, highlighting the distinct properties of each type of ...
C. Valeria L. Giosafatto, Marika Avitabile, Michela Famiglietti, Talayeh Kordjazi, Marzieh Moosavi‐Nasab, Odile F. Restaino, Loredana Mariniello   +6 more
wiley   +1 more source

Rethinking Transparency and Rigor from a Qualitative Open Science Perspective

Journal of Trial and Error, 2023
Discussions around transparency in open science focus primarily on sharing data, materials, and coding schemes, especially as these practices relate to reproducibility.
Crystal Steltenpohl, Hilary Lustick, Melanie S. Meyer, Lindsay E. Lee, Sondra M. Stegenga, Laurel Standiford Reyes, Rachel L. Renbarger   +6 more
doaj   +1 more source

Seeking transparency [PDF]

Nature Medicine, 2010
A more transparent drug approval process has the potential to reduce cost and duplicated effort, as well as ultimately improve access to effective treatments for patients.
openaire   +2 more sources

dUTPase is essential in zebrafish development and possesses several single‐nucleotide variants with pronounced structural and functional consequences

FEBS Open Bio, EarlyView.
dUTPases are involved in balancing the appropriate nucleotide pools. We showed that dUTPase is essential for normal development in zebrafish. The different zebrafish genomes contain several single‐nucleotide variations (SNPs) of the dut gene. One of the dUTPase variants displayed drastically lower protein stability and catalytic efficiency as compared ...
Viktória Perey‐Simon, Angéla Békesi, Latifa Kazzazy, Jázmin Mihály, Máté Varga, Beáta G. Vértessy, Kinga Nyíri   +6 more
wiley   +1 more source

Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis

BMC Medicine, 2019
Background Postmarketing commitments are clinical studies that pharmaceutical companies agree to conduct at the time of FDA approval, but which are not required by statute or regulation.
Joshua D. Wallach, Anita T. Luxkaranayagam, Sanket S. Dhruva, Jennifer E. Miller, Joseph S. Ross   +4 more
doaj   +1 more source

Discovery and Targeted Proteomic Studies Reveal Striatal Markers Validated for Huntington's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Clinical trials for Huntington's disease (HD) enrolling persons before clinical motor diagnosis (CMD) lack validated biomarkers. This study aimed to conduct an unbiased discovery analysis and a targeted examination of proteomic biomarkers scrutinized by clinical validation. Methods Cerebrospinal fluid was obtained from PREDICT‐HD and
Daniel Chelsky, Cara Joyce, H. Jeremy Bockholt, Paul A. Rudnick, William H. Adams, Fiona McAllister, Justin W. Smock, Michael A. Newton, Jane S. Paulsen   +8 more
wiley   +1 more source

State capture through indemnification demands? Effects on equity in the global distribution of COVID-19 vaccines

Journal of Pharmaceutical Policy and Practice, 2022
Background State capture by the pharmaceutical industry is a form of corruption whereby pharmaceutical companies shift laws or policies about their products away from the best interest of the public and toward their private benefit.
Ariel Gorodensky, Jillian C. Kohler
doaj   +1 more source

Transparent and non-transparent languages [PDF]

Folia Linguistica, 2018
Abstract Languages differ widely from one another in the extent to which they are transparent, i.e. obey one-to-one relationships between meaning and form. Transparency, in turn, is an important factor in the learnability of languages. This paper first sets out a framework for the study of transparency and subsequently studies cross-linguistic ...
Hengeveld, K., Leufkens, S.
openaire   +5 more sources

Applying an Ethical Lens to the Treatment of People With Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The practice of neurology requires an understanding of clinical ethics for decision‐making. In multiple sclerosis (MS) care, there are a wide range of ethical considerations that may arise. These involve shared decision‐making around selection of a disease‐modifying therapy (DMT), risks and benefits of well‐studied medications in comparison to
Methma Udawatta, Farrah J. Mateen
wiley   +1 more source

Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study

BMC Medicine, 2018
Background The U.S. Food and Drug Administration (FDA) often approves new drugs based on trials that use surrogate markers for endpoints, which involve certain trade-offs and may risk making erroneous inferences about the medical product’s actual ...
Joshua D. Wallach, Oriana Ciani, Alison M. Pease, Gregg S. Gonsalves, Harlan M. Krumholz, Rod S. Taylor, Joseph S. Ross   +6 more
doaj   +1 more source